Abstract:BackgroundImmune checkpoint inhibitors (ICIs) are regarded as the most promising treatment for advanced-stage non-small cell lung cancer (aNSCLC). Unfortunately, there has been no unified accuracy biomarkers and systematic model specifically identified for prognostic and severe immune-related adverse events (irAEs). Our goal was to discover new biomarkers and develop a publicly accessible method of identifying patients who may maximize benefit from ICIs.MethodsThis retrospective study enrolled 138 aNSCLC patients receiving ICIs treatment. Progression-free survival (PFS) and severe irAEs were end-points. Data of demographic features, severe irAEs, and peripheral blood inflammatory-nutritional and immune indices before and after 1 or 2 cycles of ICIs were collected. Independent factors were selected by least absolute shrinkage and selection operator (LASSO) combined with multivariate analysis, and incorporated into nomogram construction. Internal validation was performed by applying area under curve (AUC), calibration plots, and decision curve.ResultsThree nomograms with great predictive accuracy and discriminatory power were constructed in this study. Among them, two nomograms based on combined inflammatory-nutritional biomarkers were constructed for PFS (1 year-PFS and 2 year-PFS) and severe irAEs respectively, and one nomogram was constructed for 1 year-PFS based on immune indices. ESCLL nomogram (based on ECOG PS, preSII, changeCAR, changeLYM and postLDH) was constructed to assess PFS (1-, 2-year-AUC = 0.893 [95% CI 0.837-0.950], 0.828 [95% CI 0.721-0.935]). AdNLA nomogram (based on age, change-dNLR, changeLMR and postALI) was constructed to predict the risk of severe irAEs (AUC = 0.762 [95% CI 0.670-0.854]). NKT-B nomogram (based on change-CD3+CD56+CD16+NKT-like cells and change-B cells) was constructed to assess PFS (1-year-AUC = 0.872 [95% CI 0.764-0.965]). Although immune indices could not be modeled for severe irAEs prediction due to limited data, we were the first to find CD3+CD56+CD16+NKT-like cells were not only correlated with PFS but also associated with severe irAEs, which have not been reported in the study of aNSCLC-ICIs. Furthermore, our study also discovered higher change-CD4+/CD8+ ratio was significantly associated with severe irAEs.ConclusionsThese three new nomograms proceeded from non-invasive and straightforward peripheral blood data may be useful for decisions-making. CD3+CD56+CD16+NKT-like cells were first discovered to be an important biomarker for treatment and severe irAEs, and play a vital role in distinguishing the therapy response and serious toxicity of ICIs.

A Nomogram for Bladder Pain Syndrome/interstitial Cystitis Based on Netrin-1

A Nomogram Diagnostic Prediction Model of Pancreatic Metastases of Small Cell Lung Carcinoma Based on Clinical Characteristics, Radiological Features and Biomarkers

A Nomogram for Predicting the Risk of Lymph Node Metastasis in T1–2 Non-Small-cell Lung Cancer Based on PET/CT and Clinical Characteristics

Neutrophil-to-lymphocyte Ratio As a Promising Non-Invasive Biomarker for Symptom Assessment and Diagnosis of Interstitial Cystitis/bladder Pain Syndrome.

Predicting Acupuncture Efficacy in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Study on Model Development and Result Visualization

Risk factors and nomogram construction for predicting women with chronic pelvic pain:a cross-sectional population study

Development of Nomograms Related to Inﬂammatory Biomarkers to Estimate the Prognosis of Bladder Cancer after Radical Cystectomy.

Development and internal validation of a novel nomogram for predicting lymph node invasion for prostate cancer patients undergoing extended pelvic lymph node dissection

Cystoscopy, an Indispensable Tool for the Diagnosis and Prognosis of Bladder Pain Syndrome, Takes Nomograms for Predicting Recurrence.

Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer

Development and validation of a nomogram incorporating multi-parametric MRI and hematological indicators for discriminating benign from malignant central prostatic nodules: a retrospective analysis

Potential Urine and Serum Biomarkers in Patients with Bladder Pain Syndrome/Interstitial Cystitis

A Prognostic Model Incorporating Relevant Peripheral Blood Inflammation Indicator to Predict Postherpetic Neuralgia in Patients with Acute Herpes Zoster

Development of a nomogram for predicting the high-risk groups of solid-pseudopapillary neoplasms of the pancreas

New Biomarkers Exploration and Nomogram Construction of Prognostic and Immune-Related Adverse Events of Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma

Novel pretreatment nomograms based on pan-immune-inflammation value for predicting clinical outcome in patients with head and neck squamous cell carcinoma

Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment

A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors.

Development and validation of a risk nomogram model for predicting peripheral neuropathy in patients with type 2 diabetes mellitus

A Nomogram for Predicting Neurogenic Lower Urinary Tract Dysfunction in Patients with Acute Ischemic Stroke: A Retrospective Study.